Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types

Research output: Contribution to journal › Review › Research › peer-review

Standard

Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types. / Willumsen, Nicholas; Jensen, Christina; Green, George; Nissen, Neel I.; Neely, Jaclyn; Nelson, David M.; Pedersen, Rasmus S.; Frederiksen, Peder; Chen, Inna M.; Boisen, Mogens K.; Johansen, Astrid Z.; Madsen, Daniel H.; Svane, Inge Marie; Lipton, Allan; Leitzel, Kim; Ali, Suhail M.; Erler, Janine T.; Hurkmans, Daan P.; Mathijssen, Ron H.J.; Aerts, Joachim; Eslam, Mohammed; George, Jacob; Christiansen, Claus; Bissel, Mina J.; Karsdal, Morten A.

In: Cellular and Molecular Life Sciences, Vol. 79, No. 4, 204, 2022.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Willumsen, N, Jensen, C, Green, G, Nissen, NI, Neely, J, Nelson, DM, Pedersen, RS, Frederiksen, P, Chen, IM, Boisen, MK, Johansen, AZ, Madsen, DH, Svane, IM, Lipton, A, Leitzel, K, Ali, SM, Erler, JT, Hurkmans, DP, Mathijssen, RHJ, Aerts, J, Eslam, M, George, J, Christiansen, C, Bissel, MJ & Karsdal, MA 2022, 'Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types', Cellular and Molecular Life Sciences, vol. 79, no. 4, 204. https://doi.org/10.1007/s00018-022-04226-0

APA

Willumsen, N., Jensen, C., Green, G., Nissen, N. I., Neely, J., Nelson, D. M., Pedersen, R. S., Frederiksen, P., Chen, I. M., Boisen, M. K., Johansen, A. Z., Madsen, D. H., Svane, I. M., Lipton, A., Leitzel, K., Ali, S. M., Erler, J. T., Hurkmans, D. P., Mathijssen, R. H. J., ... Karsdal, M. A. (2022). Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types. Cellular and Molecular Life Sciences, 79(4), [204]. https://doi.org/10.1007/s00018-022-04226-0

Vancouver

Willumsen N, Jensen C, Green G, Nissen NI, Neely J, Nelson DM et al. Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types. Cellular and Molecular Life Sciences. 2022;79(4). 204. https://doi.org/10.1007/s00018-022-04226-0

Author

Willumsen, Nicholas ; Jensen, Christina ; Green, George ; Nissen, Neel I. ; Neely, Jaclyn ; Nelson, David M. ; Pedersen, Rasmus S. ; Frederiksen, Peder ; Chen, Inna M. ; Boisen, Mogens K. ; Johansen, Astrid Z. ; Madsen, Daniel H. ; Svane, Inge Marie ; Lipton, Allan ; Leitzel, Kim ; Ali, Suhail M. ; Erler, Janine T. ; Hurkmans, Daan P. ; Mathijssen, Ron H.J. ; Aerts, Joachim ; Eslam, Mohammed ; George, Jacob ; Christiansen, Claus ; Bissel, Mina J. ; Karsdal, Morten A. / Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types. In: Cellular and Molecular Life Sciences. 2022 ; Vol. 79, No. 4.

Bibtex

@article{82f8c6b8814d488e9f753b33bd27132a,
title = "Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types",
abstract = "Due to activation of fibroblast into cancer-associated fibroblasts, there is often an increased deposition of extracellular matrix and fibrillar collagens, e.g. type III collagen, in the tumor microenvironment (TME) that leads to tumor fibrosis (desmoplasia). Tumor fibrosis is closely associated with treatment response and poor prognosis for patients with solid tumors. To assure that the best possible treatment option is provided for patients, there is medical need for identifying patients with high (or low) fibrotic activity in the TME. Measuring unique collagen fragments such as the pro-peptides released into the bloodstream during fibrillar collagen deposition in the TME can provide a non-invasive measure of the fibrotic activity. Based on data from 8 previously published cohorts, this review provides insight into the prognostic value of quantifying tumor fibrosis by measuring the pro-peptide of type III collagen in serum of a total of 1692 patients with different solid tumor types and discusses the importance of tumor fibrosis for understanding prognosis and for potentially guiding future drug development efforts that aim at overcoming the poor outcome associated with a fibrotic TME.",
keywords = "Collagen, Fibroblast, Prognosis, Serum biomarker, Tumor fibrosis",
author = "Nicholas Willumsen and Christina Jensen and George Green and Nissen, {Neel I.} and Jaclyn Neely and Nelson, {David M.} and Pedersen, {Rasmus S.} and Peder Frederiksen and Chen, {Inna M.} and Boisen, {Mogens K.} and Johansen, {Astrid Z.} and Madsen, {Daniel H.} and Svane, {Inge Marie} and Allan Lipton and Kim Leitzel and Ali, {Suhail M.} and Erler, {Janine T.} and Hurkmans, {Daan P.} and Mathijssen, {Ron H.J.} and Joachim Aerts and Mohammed Eslam and Jacob George and Claus Christiansen and Bissel, {Mina J.} and Karsdal, {Morten A.}",
note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",
year = "2022",
doi = "10.1007/s00018-022-04226-0",
language = "English",
volume = "79",
journal = "Cellular and Molecular Life Sciences",
issn = "1420-682X",
publisher = "Birkhauser Verlag Basel",
number = "4",

}

RIS

TY - JOUR

T1 - Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types

AU - Willumsen, Nicholas

AU - Jensen, Christina

AU - Green, George

AU - Nissen, Neel I.

AU - Neely, Jaclyn

AU - Nelson, David M.

AU - Pedersen, Rasmus S.

AU - Frederiksen, Peder

AU - Chen, Inna M.

AU - Boisen, Mogens K.

AU - Johansen, Astrid Z.

AU - Madsen, Daniel H.

AU - Svane, Inge Marie

AU - Lipton, Allan

AU - Leitzel, Kim

AU - Ali, Suhail M.

AU - Erler, Janine T.

AU - Hurkmans, Daan P.

AU - Mathijssen, Ron H.J.

AU - Aerts, Joachim

AU - Eslam, Mohammed

AU - George, Jacob

AU - Christiansen, Claus

AU - Bissel, Mina J.

AU - Karsdal, Morten A.

N1 - Publisher Copyright: © 2022, The Author(s).

PY - 2022

Y1 - 2022

N2 - Due to activation of fibroblast into cancer-associated fibroblasts, there is often an increased deposition of extracellular matrix and fibrillar collagens, e.g. type III collagen, in the tumor microenvironment (TME) that leads to tumor fibrosis (desmoplasia). Tumor fibrosis is closely associated with treatment response and poor prognosis for patients with solid tumors. To assure that the best possible treatment option is provided for patients, there is medical need for identifying patients with high (or low) fibrotic activity in the TME. Measuring unique collagen fragments such as the pro-peptides released into the bloodstream during fibrillar collagen deposition in the TME can provide a non-invasive measure of the fibrotic activity. Based on data from 8 previously published cohorts, this review provides insight into the prognostic value of quantifying tumor fibrosis by measuring the pro-peptide of type III collagen in serum of a total of 1692 patients with different solid tumor types and discusses the importance of tumor fibrosis for understanding prognosis and for potentially guiding future drug development efforts that aim at overcoming the poor outcome associated with a fibrotic TME.

AB - Due to activation of fibroblast into cancer-associated fibroblasts, there is often an increased deposition of extracellular matrix and fibrillar collagens, e.g. type III collagen, in the tumor microenvironment (TME) that leads to tumor fibrosis (desmoplasia). Tumor fibrosis is closely associated with treatment response and poor prognosis for patients with solid tumors. To assure that the best possible treatment option is provided for patients, there is medical need for identifying patients with high (or low) fibrotic activity in the TME. Measuring unique collagen fragments such as the pro-peptides released into the bloodstream during fibrillar collagen deposition in the TME can provide a non-invasive measure of the fibrotic activity. Based on data from 8 previously published cohorts, this review provides insight into the prognostic value of quantifying tumor fibrosis by measuring the pro-peptide of type III collagen in serum of a total of 1692 patients with different solid tumor types and discusses the importance of tumor fibrosis for understanding prognosis and for potentially guiding future drug development efforts that aim at overcoming the poor outcome associated with a fibrotic TME.

KW - Collagen

KW - Fibroblast

KW - Prognosis

KW - Serum biomarker

KW - Tumor fibrosis

U2 - 10.1007/s00018-022-04226-0

DO - 10.1007/s00018-022-04226-0

M3 - Review

C2 - 35332383

AN - SCOPUS:85127056585

VL - 79

JO - Cellular and Molecular Life Sciences

JF - Cellular and Molecular Life Sciences

SN - 1420-682X

IS - 4

M1 - 204

ER -

ID: 305182935